Charles Schiffer
Medical Oncology · Detroit, MINPI 1417994112
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $146,654 of the $164,656 with a category attached, or 89.1%. It is spread thinly across 19 manufacturers, the largest accounting for just 16.9%. Reporting peaked in 2019 at $39,330 and has fallen 57.9% since, to $16,546 in 2025. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $1470.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$28K
- Bristol Myers Squibb$23K
- E.r. Squibb & Sons, L.L.C.$19K
- Urogen Pharma, Inc.$15K
- AstraZeneca$14K
- Astellas Pharma Global Development$13K
- plus $54K from 13 others
Across 148 payments — averaging $3079.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmacyclics LLC, An Abbvie Company$169K
- Takeda Pharmaceuticals U.S.A., Inc.$130K
- Genentech, Inc.$62K
- AstraZeneca$32K
- Pfizer$22K
- Merck$19K
- plus $22K from 2 others
What the payments were for
- Consulting fees$146,65489%
- Speaking & faculty fees$2,4001%
- Travel & lodging$13,6408%
- Food & beverage$1,9621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $27,773 |
| Bristol Myers Squibb | 13 | $22,716 |
| E.r. Squibb & Sons, L.L.C. | 18 | $18,969 |
| Urogen Pharma, Inc. | 8 | $14,579 |
| AstraZeneca | 4 | $13,605 |
| Astellas Pharma Global Development | 7 | $12,687 |
| AbbVie | 12 | $7,868 |
| Novartis | 5 | $7,284 |
| Dova Pharmaceuticals | 6 | $7,248 |
| Agios Pharmaceuticals, Inc. | 8 | $5,657 |
| Eli Lilly | 1 | $5,250 |
| TG Therapeutics, Inc. | 2 | $5,063 |
| Y-mabs Therapeutics, Inc. | 1 | $4,650 |
| Astellas Pharma US Inc | 2 | $3,791 |
| Innate Pharma, Inc | 1 | $2,400 |
| Acrotech Biopharma Inc. | 1 | $2,025 |
| Pfizer | 3 | $1,967 |
| Biomerieux Inc | 1 | $1,000 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,656 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Detroit
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Ahmed KasebDetroit$107K
- Bassel El-RayesDetroit$76K
- Haythem AliDetroit$34K
- Dipesh UpretyDetroit$21K
- Clara HwangDetroit$16K
- Amy WeiseDetroit$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.